{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:01:25Z","timestamp":1794744085196,"version":"4.9.1"},"reference-count":112,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Mass spectrometry (MS) is an emerging tool in multiple myeloma that detects and quantifies monoclonal proteins in the peripheral blood with sensitivity several orders of magnitude greater than conventional serum protein electrophoresis and immunofixation. Both intact light-chain (top-down) and clonotypic peptide (bottom-up) MS approaches have demonstrated sensitivity comparable to, or even surpassing, bone marrow (BM)\u2013based assessments using next-generation flow cytometry or sequencing. However, due to the delayed clearance of paraproteins, MS may be less informative for early response assessment, underscoring the need to define the optimal timing for evaluation. MS assays have now transitioned from research settings to commercial availability, addressing the clinical demand for sensitive, noninvasive monitoring tools that avoid reliance on BM biopsies. This review provides an overview of MS and explores its growing role in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015685","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T20:09:36Z","timestamp":1757362176000},"page":"6593-6603","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["Clinical applications of mass spectrometry in multiple myeloma"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4070-1819","authenticated-orcid":false,"given":"Benjamin A.","family":"Derman","sequence":"first","affiliation":[{"name":"1Section of Hematology\/Oncology, The University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3623-7491","authenticated-orcid":false,"given":"Andrew J.","family":"Yee","sequence":"additional","affiliation":[{"name":"2Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"issue":"3","key":"2025122311211479500_bib1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/ejh.12829","article-title":"Association between complete response and outcomes in transplant-eligible myeloma patients in the era of novel agents","volume":"98","author":"van de Velde","year":"2017","journal-title":"Eur J Haematol"},{"issue":"3","key":"2025122311211479500_bib2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/blood-2011-01-332320","article-title":"Long-term prognostic significance of response in multiple myeloma after stem cell transplantation","volume":"118","author":"Martinez-Lopez","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2025122311211479500_bib3","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood-2010-09-307645","article-title":"Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients","volume":"117","author":"Gay","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2025122311211479500_bib4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/hematology.2021000230","article-title":"Minimal residual disease in multiple myeloma: why, when, where","volume":"2021","author":"Yee","year":"2021","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"1","key":"2025122311211479500_bib5","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1186\/s12885-020-07077-9","article-title":"Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma","volume":"20","author":"Ching","year":"2020","journal-title":"BMC Cancer"},{"issue":"10","key":"2025122311211479500_bib6","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"2025122311211479500_bib7","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"2025122311211479500_bib8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41375-020-01012-4","article-title":"International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials","volume":"35","author":"Costa","year":"2021","journal-title":"Leukemia"},{"issue":"12","key":"2025122311211479500_bib9","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/bmt.2016.222","article-title":"Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis","volume":"51","author":"Landgren","year":"2016","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"2025122311211479500_bib10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"issue":"23","key":"2025122311211479500_bib11","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"2025122311211479500_bib12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood.2024024371","article-title":"EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma","volume":"144","author":"Landgren","year":"2024","journal-title":"Blood"},{"issue":"11","key":"2025122311211479500_bib13","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1200\/JCO-24-02020","article-title":"Minimal residual disease-based end point for accelerated assessment of clinical trials in multiple myeloma: a pooled analysis of individual patient data from multiple randomized trials","volume":"43","author":"Shi","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025122311211479500_bib14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1182\/blood.2024025421","article-title":"MRD accelerating myeloma drug development","volume":"144","author":"Costa","year":"2024","journal-title":"Blood"},{"issue":"11","key":"2025122311211479500_bib15","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","article-title":"Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"issue":"4","key":"2025122311211479500_bib16","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"issue":"5","key":"2025122311211479500_bib17","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa2505133","article-title":"Measurable residual disease\u2013guided therapy in newly diagnosed myeloma","volume":"393","author":"Perrot","year":"2025","journal-title":"N Engl J Med"},{"issue":"23","key":"2025122311211479500_bib18","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2025122311211479500_bib19","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41408-024-01156-x","article-title":"Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)","volume":"14","author":"Derman","year":"2024","journal-title":"Blood Cancer J"},{"issue":"10","key":"2025122311211479500_bib20","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1200\/JCO.20.01814","article-title":"Evaluation of sustained minimal residual disease negativity with daratumumab-combination regimens in relapsed and\/or refractory multiple myeloma: analysis of POLLUX and CASTOR","volume":"39","author":"Avet-Loiseau","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025122311211479500_bib21","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE","volume":"139","author":"San-Miguel","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2025122311211479500_bib22","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1016\/S2352-3026(21)00130-7","article-title":"Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial","volume":"8","author":"Diamond","year":"2021","journal-title":"Lancet Haematol"},{"issue":"22","key":"2025122311211479500_bib23","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.4431.4431","article-title":"The clinical impact of macrofocal disease in multiple myeloma differs between presentation and relapse","volume":"128","author":"Rasche","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2025122311211479500_bib24","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/ajh.25755","article-title":"Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: a study of the Greco-Israeli Collaborative Myeloma Working Group","volume":"95","author":"Katodritou","year":"2020","journal-title":"Am J Hematol"},{"issue":"3","key":"2025122311211479500_bib25","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1182\/bloodadvances.2021005822","article-title":"Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma","volume":"6","author":"Mohan","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"2025122311211479500_bib26","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.hoc.2023.12.009","article-title":"Measurable residual disease and decision-making in multiple myeloma","volume":"38","author":"Derman","year":"2024","journal-title":"Hematol Oncol Clin North Am"},{"issue":"24","key":"2025122311211479500_bib27","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1182\/blood.2019002610","article-title":"Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy","volume":"134","author":"Sanoja-Flores","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2025122311211479500_bib28","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1182\/blood-2023-182410","article-title":"Early peripheral blood minimal residual disease status by NGS in patients with newly diagnosed multiple myeloma (MM) on a phase 2 trial receiving elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd)","volume":"142","author":"Derman","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2025122311211479500_bib29","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1038\/s41375-019-0469-x","article-title":"Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients","volume":"33","author":"Mithraprabhu","year":"2019","journal-title":"Leukemia"},{"issue":"8","key":"2025122311211479500_bib30","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1038\/s41375-018-0115-z","article-title":"Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing","volume":"32","author":"Guo","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"2025122311211479500_bib31","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/bloodadvances.2022008005","article-title":"Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MM","volume":"7","author":"Kriegsmann","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"2025122311211479500_bib32","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood.2025029234","article-title":"Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment","volume":"146","author":"Lasa","year":"2025","journal-title":"Blood"},{"key":"2025122311211479500_bib33","doi-asserted-by":"crossref","first-page":"786451","DOI":"10.3389\/fonc.2022.786451","article-title":"Assessment of molecular residual disease using circulating tumor DNA to identify multiple myeloma patients at high risk of relapse","volume":"12","author":"Dhakal","year":"2022","journal-title":"Front Oncol"},{"issue":"3","key":"2025122311211479500_bib34","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/ejh.13358","article-title":"Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients","volume":"104","author":"Vrabel","year":"2020","journal-title":"Eur J Haematol"},{"issue":"4","key":"2025122311211479500_bib35","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1515\/cclm-2019-1105","article-title":"An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part II: limit of detection and follow-up of patients with small M-proteins","volume":"58","author":"Jacobs","year":"2020","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"2025122311211479500_bib36","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/leu.2008.307","article-title":"International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders","volume":"23","author":"Dispenzieri","year":"2009","journal-title":"Leukemia"},{"issue":"1","key":"2025122311211479500_bib37","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s43586-022-00175-x","article-title":"Liquid chromatography\u2013tandem mass spectrometry for clinical diagnostics","volume":"2","author":"Thomas","year":"2022","journal-title":"Nat Rev Methods Primer"},{"issue":"9","key":"2025122311211479500_bib38","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.mayocp.2020.06.029","article-title":"Amyloid typing by mass spectrometry in clinical practice: a comprehensive review of 16,175 samples","volume":"95","author":"Dasari","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"2025122311211479500_bib39","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1021\/pr400985k","article-title":"Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy","volume":"13","author":"Barnidge","year":"2014","journal-title":"J Proteome Res"},{"issue":"2","key":"2025122311211479500_bib40","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-021-00408-4","article-title":"Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee report","volume":"11","author":"Murray","year":"2021","journal-title":"Blood Cancer J"},{"issue":"3","key":"2025122311211479500_bib41","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/clinchem\/hvz041","article-title":"Mass spectrometry for identification, monitoring, and minimal residual disease detection of M-proteins","volume":"66","author":"Zajec","year":"2020","journal-title":"Clin Chem"},{"issue":"10","key":"2025122311211479500_bib42","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1373\/clinchem.2015.253740","article-title":"Comprehensive assessment of M-proteins using nanobody enrichment coupled to MALDI-TOF mass spectrometry","volume":"62","author":"Mills","year":"2016","journal-title":"Clin Chem"},{"issue":"1","key":"2025122311211479500_bib43","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1515\/cclm-2020-0581","article-title":"Automation and validation of a MALDI-TOF MS (Mass-Fix) replacement of immunofixation electrophoresis in the clinical lab","volume":"59","author":"Kohlhagen","year":"2020","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"2025122311211479500_bib44","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.mayocp.2021.07.024","article-title":"Detection of plasma cell disorders by mass spectrometry: a comprehensive review of 19,523 cases","volume":"97","author":"Dasari","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"2025122311211479500_bib45","unstructured":"ThermoFisher Scientific\n          . Binding Site Launches EXENT Solution with IVDR Certification. Accessed 15 September 2025. https:\/\/www.thermofisher.com\/bindingsite\/wo\/en\/news\/exent-launch.html."},{"issue":"suppl 1","key":"2025122311211479500_bib46","doi-asserted-by":"crossref","first-page":"12446","DOI":"10.1182\/blood-2022-160249","article-title":"Comparison of the analytical performance of EXENT, a mass spectrometry-based assessment of M-protein, to SPEP and NGS-based MRD in multiple myeloma patient samples","volume":"140","author":"Li","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2025122311211479500_bib47","doi-asserted-by":"crossref","first-page":"e590","DOI":"10.1038\/bcj.2017.75","article-title":"High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma","volume":"7","author":"Mills","year":"2017","journal-title":"Blood Cancer J"},{"key":"2025122311211479500_bib48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jmsacl.2024.02.002","article-title":"Endogenous monoclonal immunoglobulins analyzed using the EXENT solution and LC-MS","volume":"32","author":"Barnidge","year":"2024","journal-title":"J Mass Spectrom Adv Clin Lab"},{"issue":"1","key":"2025122311211479500_bib49","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-024-00995-y","article-title":"Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry","volume":"14","author":"Giles","year":"2024","journal-title":"Blood Cancer J"},{"issue":"8","key":"2025122311211479500_bib50","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1021\/acs.jproteome.0c01022","article-title":"Mass spectrometry provides a highly sensitive noninvasive means of sequencing and tracking M-protein in the blood of multiple myeloma patients","volume":"20","author":"McDonald","year":"2021","journal-title":"J Proteome Res"},{"issue":"12","key":"2025122311211479500_bib51","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1515\/cclm-2024-0306","article-title":"An automated workflow based on data independent acquisition for practical and high-throughput personalized assay development and minimal residual disease monitoring in multiple myeloma patients","volume":"62","author":"Wijnands","year":"2024","journal-title":"Clin Chem Lab Med"},{"issue":"6","key":"2025122311211479500_bib52","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/clinchem\/hvab017","article-title":"Clonotypic features of rearranged immunoglobulin genes yield personalized biomarkers for minimal residual disease monitoring in multiple myeloma","volume":"67","author":"Langerhorst","year":"2021","journal-title":"Clin Chem"},{"issue":"18","key":"2025122311211479500_bib53","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1158\/1078-0432.CCR-21-0649","article-title":"A personalized mass spectrometry-based assay to monitor M-protein in patients with multiple myeloma (EasyM)","volume":"27","author":"Liyasova","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"2025122311211479500_bib54","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/blood-2023-179382","article-title":"Blood-based mass spectrometry MRD tracking (M-InSight) in multiple myeloma patients from clinical trial NCT02513186","volume":"142","author":"Di Stefano","year":"2023","journal-title":"Blood"},{"issue":"6","key":"2025122311211479500_bib55","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1158\/1078-0432.CCR-23-2767","article-title":"Monitoring minimal residual disease in patients with multiple myeloma by targeted tracking serum M-protein using mass spectrometry (EasyM)","volume":"30","author":"Fan","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2025122311211479500_bib56","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41408-022-00624-6","article-title":"Mass-fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 \/07LT)","volume":"12","author":"Dispenzieri","year":"2022","journal-title":"Blood Cancer J"},{"issue":"11","key":"2025122311211479500_bib57","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1182\/bloodadvances.2021006762","article-title":"Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma","volume":"6","author":"Puig","year":"2022","journal-title":"Blood Adv"},{"issue":"23","key":"2025122311211479500_bib58","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1182\/blood.2024024995","article-title":"Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma","volume":"144","author":"Puig","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025122311211479500_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00772-9","article-title":"Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma","volume":"13","author":"Mai","year":"2023","journal-title":"Blood Cancer J"},{"issue":"9","key":"2025122311211479500_bib60","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood.2024024041","article-title":"Mass spectrometry\u2013based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma","volume":"144","author":"Kubicki","year":"2024","journal-title":"Blood"},{"issue":"12","key":"2025122311211479500_bib61","first-page":"4056","article-title":"Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM-CESAR trial","volume":"109","author":"Puig","year":"2024","journal-title":"Haematologica"},{"issue":"1","key":"2025122311211479500_bib62","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41408-024-01045-3","article-title":"Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant","volume":"14","author":"Derman","year":"2024","journal-title":"Blood Cancer J"},{"issue":"9","key":"2025122311211479500_bib67","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jamaoncol.2022.2424","article-title":"Elotuzumab and weekly carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma without transplant intent: a phase 2 measurable residual disease\u2013adapted study","volume":"8","author":"Derman","year":"2022","journal-title":"JAMA Oncol"},{"issue":"5","key":"2025122311211479500_bib68","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/bjh.16443","article-title":"Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma","volume":"189","author":"Eveillard","year":"2020","journal-title":"Br J Haematol"},{"issue":"2","key":"2025122311211479500_bib69","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/bjh.17195","article-title":"Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma","volume":"193","author":"Abeykoon","year":"2021","journal-title":"Br J Haematol"},{"issue":"2","key":"2025122311211479500_bib70","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-021-00418-2","article-title":"Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation","volume":"11","author":"Derman","year":"2021","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"2025122311211479500_bib71","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1182\/blood-2021-151557","article-title":"Assessment of treatment response by Ife, next generation flow cytometry and mass spectrometry coupled with liquid chromatography in the GEM2012MENOS65 clinical trial","volume":"138","author":"Puig","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2025122311211479500_bib63","first-page":"764","article-title":"Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma","volume":"110","author":"Zhao","year":"2025","journal-title":"Haematologica"},{"issue":"1","key":"2025122311211479500_bib64","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41408-023-00803-z","article-title":"Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry","volume":"13","author":"Noori","year":"2023","journal-title":"Blood Cancer J"},{"issue":"3","key":"2025122311211479500_bib65","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1021\/acs.jproteome.7b00890","article-title":"Development of a targeted mass-spectrometry serum assay to quantify M-protein in the presence of therapeutic monoclonal antibodies","volume":"17","author":"Zajec","year":"2018","journal-title":"J Proteome Res"},{"issue":"9","key":"2025122311211479500_bib66","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1182\/blood.2024025189","article-title":"An ATLAS to map MRD with peripheral blood","volume":"144","author":"Yee","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2025122311211479500_bib72","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.24.00635","article-title":"Minimally invasive assessment of peripheral residual disease during maintenance or observation in transplant-eligible patients with multiple myeloma","volume":"43","author":"Lasa","year":"2025","journal-title":"J Clin Oncol"},{"issue":"23","key":"2025122311211479500_bib73","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood.2022016170","article-title":"MRD in multiple myeloma: does CR really matter?","volume":"140","author":"Paiva","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2025122311211479500_bib74","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ajh.27526","article-title":"Clinical significance of complete remission and measurable residual disease in relapsed\/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy","volume":"100","author":"Zabaleta","year":"2025","journal-title":"Am J Hematol"},{"issue":"4","key":"2025122311211479500_bib75","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1111\/bjh.19589","article-title":"Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T-cells","volume":"205","author":"Ortiz de Landazuri","year":"2024","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2025122311211479500_bib76","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1182\/blood-2023-179742","article-title":"Evaluation of easym, a clonotypic mass spectrometry assay, and euroflow minimal residual disease assessment in multiple myeloma","volume":"142","author":"Zhao","year":"2023","journal-title":"Blood"},{"issue":"9","key":"2025122311211479500_bib77","doi-asserted-by":"crossref","first-page":"e628","DOI":"10.1016\/j.clml.2025.04.017","article-title":"Blood-based measurable residual disease by clonotypic mass spectrometry is prognostic in patients with multiple myeloma undergoing autologous hematopoietic cell transplant","volume":"25","author":"Slade","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"2025122311211479500_bib78","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/bmt.2012.151","article-title":"Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients\u2019 monitoring after transplantation","volume":"48","author":"Zamarin","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2025122311211479500_bib79","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/bmt.2013.150","article-title":"Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma","volume":"49","author":"Fern\u00e1ndez de Larrea","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2025122311211479500_bib80","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41375-018-0271-1","article-title":"Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse","volume":"33","author":"Sidana","year":"2019","journal-title":"Leukemia"},{"issue":"7","key":"2025122311211479500_bib81","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.2023022083","article-title":"Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma","volume":"143","author":"Guerrero","year":"2024","journal-title":"Blood"},{"issue":"7","key":"2025122311211479500_bib82","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1182\/blood.2023022080","article-title":"Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma","volume":"143","author":"D\u2019Agostino","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025122311211479500_bib83","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41408-025-01219-7","article-title":"Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy","volume":"15","author":"Costa","year":"2025","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"2025122311211479500_bib84","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1182\/blood-2023-189022","article-title":"Will survival improve by treating multiple myeloma patients at MRD relapse? the Remnant study","volume":"142","author":"Askeland","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2025122311211479500_bib85","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.yao.2022.02.012","article-title":"Moving toward a cure in multiple myeloma: eradication of measurable residual disease","volume":"2","author":"Derman","year":"2022","journal-title":"Adv Oncol"},{"issue":"8","key":"2025122311211479500_bib86","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41408-020-00353-8","article-title":"Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma","volume":"10","author":"Paquin","year":"2020","journal-title":"Blood Cancer J"},{"issue":"suppl 16","key":"2025122311211479500_bib87","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1200\/JCO.2025.43.16_suppl.7501","article-title":"Subcutaneous daratumumab (Dara) + bortezomib\/lenalidomide\/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): analysis of sustained minimal residual disease negativity in the phase 3 PERSEUS trial","volume":"43","author":"Moreau","year":"2025","journal-title":"J Clin Oncol"},{"issue":"25","key":"2025122311211479500_bib88","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-term (\u22655-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11","key":"2025122311211479500_bib89","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematol"},{"issue":"1","key":"2025122311211479500_bib90","doi-asserted-by":"crossref","first-page":"10396","DOI":"10.1038\/s41467-024-54543-0","article-title":"Multiple myeloma long-term survivors exhibit sustained immune alterations decades after first-line therapy","volume":"15","author":"Lutz","year":"2024","journal-title":"Nat Commun"},{"key":"2025122311211479500_bib91","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S2152-2650(24)01858-5","article-title":"OA-17 liquid chromatography mass spectrometry (LC-MS) for identification of exceptional responders in newly diagnosed multiple myeloma (NDMM)","volume":"24","author":"Kubicki","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"2025122311211479500_bib92","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1182\/blood-2024-203566","article-title":"Clonotypic peptide mass spectrometry to define functional cure in patients with multiple myeloma undergoing maintenance cessation","volume":"144","author":"Derman","year":"2024","journal-title":"Blood"},{"key":"2025122311211479500_bib93","first-page":"107","article-title":"Using QIP-MS to guide the timing of MRD testing in patients with multiple myeloma: a budget impact analysis from the French payer perspective","volume":"17","author":"Siegfried","year":"2025","journal-title":"Clin Outcomes Res CEOR"},{"issue":"6","key":"2025122311211479500_bib94","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1515\/cclm-2015-1031","article-title":"Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference","volume":"54","author":"McCudden","year":"2016","journal-title":"Clin Chem Lab Med"},{"issue":"6","key":"2025122311211479500_bib95","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1515\/cclm-2015-0888","article-title":"Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA)","volume":"54","author":"van de Donk","year":"2016","journal-title":"Clin Chem Lab Med"},{"issue":"4","key":"2025122311211479500_bib96","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/jalm\/jfae028","article-title":"Isatuximab-specific immunofixation electrophoresis assay to remove interference in serum M-protein measurement in patients with multiple myeloma","volume":"9","author":"Thoren","year":"2024","journal-title":"J Appl Lab Med"},{"key":"2025122311211479500_bib97","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cca.2019.02.017","article-title":"MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins","volume":"492","author":"Moore","year":"2019","journal-title":"Clin Chim Acta"},{"issue":"2","key":"2025122311211479500_bib98","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/jalm\/jfae142","article-title":"Distinguishing daratumumab from endogenous monoclonal proteins in serum from multiple myeloma patients using an automated mass spectrometry system","volume":"10","author":"Barnidge","year":"2025","journal-title":"J Appl Lab Med"},{"issue":"15","key":"2025122311211479500_bib99","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1182\/bloodadvances.2021006713","article-title":"Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma","volume":"6","author":"Martin","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"2025122311211479500_bib100","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.3324\/haematol.2017.171694","article-title":"Pseudo-monoclonal gammopathy: a report of four cases","volume":"102","author":"Jawad","year":"2017","journal-title":"Haematologica"},{"issue":"7","key":"2025122311211479500_bib101","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.3324\/haematol.2013.084350","article-title":"Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution","volume":"98","author":"Tovar","year":"2013","journal-title":"Haematologica"},{"issue":"6","key":"2025122311211479500_bib102","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood.2021013794","article-title":"Redefining nonmeasurable multiple myeloma using mass spectrometry","volume":"139","author":"Giles","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2025122311211479500_bib103","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1182\/blood.2024026028","article-title":"Soluble B-cell maturation antigen levels for disease monitoring in oligosecretory and nonsecretory relapsed multiple myeloma","volume":"145","author":"Ikeda","year":"2025","journal-title":"Blood"},{"issue":"1","key":"2025122311211479500_bib104","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41375-018-0194-x","article-title":"Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients","volume":"33","author":"Kumar","year":"2019","journal-title":"Leukemia"},{"issue":"10","key":"2025122311211479500_bib105","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1038\/s41375-020-0940-8","article-title":"N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression","volume":"34","author":"Dispenzieri","year":"2020","journal-title":"Leukemia"},{"key":"2025122311211479500_bib106","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fphys.2017.00149","article-title":"Analysis of a compartmental model of endogenous immunoglobulin G metabolism with application to multiple myeloma","volume":"8","author":"Kendrick","year":"2017","journal-title":"Front Physiol"},{"issue":"4","key":"2025122311211479500_bib107","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3390\/antib9040070","article-title":"Fc engineering strategies to advance IgA antibodies as therapeutic agents","volume":"9","author":"Van Tetering","year":"2020","journal-title":"Antibodies"},{"issue":"12","key":"2025122311211479500_bib112","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/ki.2011.94","article-title":"The biology of immunoglobulin free light chains and kidney injury","volume":"79","author":"Basnayake","year":"2011","journal-title":"Kidney Int"},{"issue":"9","key":"2025122311211479500_bib108","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"2025122311211479500_bib109","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s40262-017-0598-1","article-title":"Influence of disease and patient characteristics on daratumumab exposure and clinical outcomes in relapsed or refractory multiple myeloma","volume":"57","author":"Yan","year":"2018","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"2025122311211479500_bib110","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/s41375-021-01501-0","article-title":"Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab","volume":"36","author":"Abdallah","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"2025122311211479500_bib111","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1158\/2643-3230.BCD-23-0044","article-title":"Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel","volume":"4","author":"Paiva","year":"2023","journal-title":"Blood Cancer Discov"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6593\/2476893\/blooda_adv-2024-015685-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6593\/2476893\/blooda_adv-2024-015685-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T16:21:37Z","timestamp":1766506897000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/24\/6593\/547165\/Clinical-applications-of-mass-spectrometry-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":112,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025,12,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015685","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,23]]},"published":{"date-parts":[[2025,12,23]]}}}